Navigation Links
Onyx Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference
Date:5/12/2009

EMERYVILLE, Calif., May 12 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Deutsche Bank 34th Annual Health Care Conference on Tuesday, May 19, at 2:35 p.m. Eastern Time. Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/wt/page/event_calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available one hour following the conclusion of the presentation through June 19, 2009.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
2. Vion Pharmaceuticals Reports 2009 First Quarter Results
3. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
4. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
5. Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
6. Photos: Generic Pharmaceuticals Saved $734 Billion over Last Decade
7. VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
8. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
10. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
11. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... Yost, will begin serving as new board chair for Orange County health care ... serve the remainder of soon-to-be former chair Mark Refowitz’s term, which runs through ...
(Date:3/28/2017)... ... 28, 2017 , ... Neurotechnology , a provider of ... attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and the ... face recognition to enable users to check in and out from anywhere via ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER ... ions found in power plant water and steam. , Chlorides and sulfates cause ... boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at low ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & Clients of ... for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser Event ... billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a direct relation ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... to achieve the “perfect smile.” The National Association of Dental Laboratories (NADL) is ... dentists should be aware of when utilizing dental laboratories and technicians that create ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... England , March 28, 2017 ... collaborative research with Cambridge ... Therapeutics Consortium   The Milner Therapeutics Institute today ... Consortium. Elysium Health has committed significant investment for collaborative projects ... the next four years. This is the first major research ...
(Date:3/27/2017)... March 27, 2017 Therapix ... pharmaceutical company specializing in the development of cannabinoid-based drugs, ... in the United States ... representing 40 ordinary shares of the Company, at ... Therapix has granted the underwriters a 45-day over-allotment ...
Breaking Medicine Technology: